We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Trillium Therapeutics Inc | NASDAQ:TRIL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.44 | 20.33 | 18.30 | 0 | 01:00:00 |
CUSIP No.
|
89620X506
|
Schedule 13G
|
1
|
NAMES OF REPORTING PERSONS
|
|
|
||
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
|
|
|
|||
Thomas D. Mottola
|
|
|
|||
|
|
||||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
||||
(a)
☐
|
|||||
(b)☒
|
|
|
|||
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|||
|
|
||||
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
United States
|
|
|
|||
|
|
||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
5
|
SOLE VOTING POWER
|
|
|
|
0
|
|
|
|||
|
|
||||
6
|
SHARED VOTING POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
7
|
SOLE DISPOSITIVE POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
8
|
SHARED DISPOSITIVE POWER
|
|
|
||
0
|
|
|
|||
|
|
||||
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
0
|
|
|
|||
|
|
||||
10
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
||
☐
|
|
|
|||
|
|
||||
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
||
0.0%
|
|
|
|||
|
|
||||
12
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
||
IN
|
|
|
|||
|
|
CUSIP No.
|
89620X506
|
Schedule 13G
|
Item 1(a).
|
|
Name of Issuer:
|
|
|
|
|
|
Trillium Therapeutics Inc. (the "Issuer")
|
|
|
|
Item 1(b).
|
|
Address of Issuer's Principal Executive Offices:
|
|
|
|
|
|
96 Skyway Avenue, Toronto, Ontario, Canada M9W 4Y9
|
|
|
|
Item 2(a).
|
|
Name of Person Filing:
|
|
|
|
|
|
Thomas D. Mottola
|
|
|
|
Item 2(b).
|
|
Address of Principal Business Office, or if None, Residence:
|
|
|
|
|
|
c/o Andrews Management
23 Old Kings Highway, South Suite 200
Darien, CT 06820
|
|
|
|
Item 2(c).
|
|
Citizenship:
|
|
|
|
|
|
United States citizen
|
|
|
|
Item 2(d).
|
|
Title of Class of Securities:
|
|
|
|
|
|
Common Shares, no par value
|
|
|
|
Item 2(e).
|
|
CUSIP Number:
|
|
|
|
|
|
89620X506
|
|
|
|
Item 3.
|
|
If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
|
(a)
|
|
☐
|
Broker or dealer registered under Section 15 of the Exchange Act.
|
|
|
|
|
(b)
|
|
☐
|
Bank as defined in Section 3(a)(6) of the Exchange Act.
|
|
|
|
|
(c)
|
|
☐
|
Insurance company as defined in Section 3(a)(19) of the Exchange Act.
|
|
|
|
|
(d)
|
|
☐
|
Investment company registered under Section 8 of the Investment Company Act.
|
(e)
|
|
☐
|
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
|
|
|
|
|
(f)
|
|
☐
|
An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
|
|
|
|
|
(g)
|
|
☐
|
A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
|
|
|
|
|
(h)
|
|
☐
|
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
|
(i)
|
|
☐
|
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
|
|
|
|
|
(j)
|
|
☐
|
A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
|
|
|
|
|
(k)
|
|
☐
|
Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
|
Item 4.
|
|
|
Ownership.
|
(a)
|
|
|
Amount beneficially owned**:
|
|
|
|
|
|
|
|
0
|
|
|
|
|
(b)
|
|
|
Percent of class**:
|
|
|
|
|
|
|
|
0.0%
|
(c)
|
|
|
Number of shares as to which such person has**:
|
|
|
|
|
|
|
|
|
|
|
|
(i)
|
Sole power to vote or to direct the vote:
|
0
|
|
|
|
|
|
|
|
|
|
(ii)
|
Shared power to vote or to direct the vote
|
0
|
|
|
|
(iii)
|
Sole power to dispose or to direct the disposition of
|
0
|
|
|
|
|
|
|
|
|
|
(iv)
|
Shared power to dispose or to direct the disposition of
|
0
|
Item 5.
|
Ownership of Five Percent or Less of a Class.
|
|
As of December 31, 2016, Thomas D. Mottola no longer beneficially owns any shares of the Issuer.
|
Item 6.
|
Ownership of More Than Five Percent on Behalf of Another Person.
|
|
N/A
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
|
|
N/A
|
Item 8.
|
Identification and Classification of Members of the Group.
|
|
N/A
|
Item 9.
|
Notice of Dissolution of Group.
|
|
N/A
|
Item 10.
|
Certifications.
|
CUSIP No.
|
89620X506
|
Schedule 13G
|
1 Year Trillium Therapeutics Chart |
1 Month Trillium Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions